124 related articles for article (PubMed ID: 6685627)
1. Clinical staging and therapeutic results in multiple myeloma.
Santoro A; Schieppati G; Franchi F; Valagussa P; Monfardini S
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1353-9. PubMed ID: 6685627
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone.
Marmont F; Levis A; Falda M; Resegotti L
Ann Oncol; 1991 Mar; 2(3):191-5. PubMed ID: 2043489
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
4. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
[TBL] [Abstract][Full Text] [Related]
5. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
6. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
7. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
[TBL] [Abstract][Full Text] [Related]
8. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
11. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
Sakalová A; Bock PR; Dedík L; Hanisch J; Schiess W; Gazová S; Chabronová I; Holomanova D; Mistrík M; Hrubisko M
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S38-44. PubMed ID: 11561871
[TBL] [Abstract][Full Text] [Related]
12. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
[TBL] [Abstract][Full Text] [Related]
13. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
[TBL] [Abstract][Full Text] [Related]
16. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
[TBL] [Abstract][Full Text] [Related]
17. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
Paule B; Quillard J; Bisson M; Massias P
Nouv Rev Fr Hematol (1978); 1987; 29(6):391-6. PubMed ID: 2454453
[TBL] [Abstract][Full Text] [Related]
18. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
19. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
20. [Polychemotherapy in multiple myeloma. The COMPA protocol].
Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
